02 May 2003
PARP and myocardial ischaemia-reperfusion injury
C. ThiemermannMed Sci Monit 2003; 9(1): 70-0 :: ID: 15213
Abstract
There is now good evidence that inhibitors of PARP activity reduce the tissue injury caused by regional myocardial ischemia and reperfusion. For instance, various, chemically distinct inhibitors of PARP activity [including 3-aminobenzamide (3-AB) and 1, 5-dihydroxyisoquinoline (ISO)] reduce the infarct size caused by ischaemia-reperfusion injury of the rabbit heart in vivo. In addition, 3-AB and ISO also reduce the infarct size caused by regional myocardial ischaemia and reperfusion in the heart of the rat in vivo and in vitro. Moreover, ISO reduces the contractile dysfunction, the fall in high-energy phosphates caused by global myocardial ischemia and reperfusion in the rat heart. Exposure of human cardiac myoblasts in vitro results in an increase in PARP activity, and secondary cell death. Inhibition of this increase in PARP activity reduces the impairment in mitochondrial respiration as well as the associated cell death caused by these reactive oxygen species. The tissue injury caused by coronary artery occlusion and reperfusion in PARP-1 knock out mice is substantially reduced (when compared to their wild-type litter mates). Potent, water-soluble inhibitors of PARP activity (including 5-aminoisoquinolinone, PJ-34 and others) cause a substantial reduction in myocardial infarct size in the rat in vivo. Taken together, these findings support the view that (1) the excessive activation of PARP contributes to myocardial reperfusion injury, and (2) potent, water-soluble inhibitors of PARP activity may be useful in conditions associated with acute myocardial ischemia and reperfusion. These conditions may include acute myocardial infarction, coronary angioplasty, cardiac transplantation and bypass heart surgery. References: 1.Thiemermann C et al: Proc Natl Acad Sci USA, 1997; 94: 679-683
Keywords: Heart, Infarction, 5-AIQ, cardiac ischemia, ischaemia
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952